#Eli Lilly
Total 10 articles
Samsung Biologics and Eli Lilly will co-establish a Lilly Gateway Labs site in Songdo, Incheon by 2027. What does this mean for Korea's biotech ecosystem and global pharma strategy?
Novo Nordisk's supply chain failures and clinical disappointments have given Eli Lilly a commanding lead in the $100 billion weight-loss drug market. What this means for investors and patients.
Trump announces Eli Lilly will build six US plants, signaling a major shift in pharmaceutical manufacturing. We analyze the implications for global supply chains and competition.
PRISM by Liabooks
Place your ad in this space
[email protected]
The China obesity drug price war 2026 is heating up as companies slash prices by 80%. Discover how Novo Nordisk and Eli Lilly are responding to local competition.
Insilico Medicine Hong Kong IPO 2025 debuts with a 46% stock jump, raising $300m. The firm eyes expansion into the LLM market to drive future growth.
Celltrion expects its 2025 operating profit to exceed 1 trillion won for the first time. Explore the drivers behind this record growth and its US market strategy.
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
PRISM by Liabooks
Place your ad in this space
[email protected]
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.
The US FDA has approved the first-ever pill form of Novo Nordisk's blockbuster weight-loss drug, Wegovy. Showing comparable results to the injection in trials, the daily pill is set to launch in January 2026.
The FDA has approved a once-daily pill version of Novo Nordisk's blockbuster weight-loss drug Wegovy, offering a new option versus the weekly shot and escalating competition with Eli Lilly.
